Goals and motivations of families pursuing oral immunotherapy for food allergy

2019 ◽  
Vol 7 (2) ◽  
pp. 662-663.e18 ◽  
Author(s):  
Joan H. Dunlop ◽  
Corinne A. Keet
Children ◽  
2021 ◽  
Vol 8 (6) ◽  
pp. 497
Author(s):  
Aikaterini Anagnostou

Background: Food allergies are common, affecting 1 in 13 school children in the United States and their prevalence is increasing. Many misconceptions exist with regards to food allergy prevention, diagnosis and management. Objective: The main objective of this review is to address misconceptions with regards to food allergies and discuss the optimal, evidence-based approach for patients who carry this diagnosis. Observations: Common misconceptions in terms of food allergy prevention include beliefs that breastfeeding and delayed introduction of allergenic foods prevent the development of food allergies. In terms of diagnosis, statements such as ‘larger skin prick tests or/and higher levels of food-specific IgE can predict the severity of food-induced allergic reactions’, or ‘Tryptase is always elevated in food-induced anaphylaxis’ are inaccurate. Additionally, egg allergy is not a contraindication for receiving the influenza vaccine, food-allergy related fatalities are rare and peanut oral immunotherapy, despite reported benefits, is not a cure for food allergies. Finally, not all infants with eczema will develop food allergies and epinephrine auto-injectors may unfortunately be both unavailable and underused in food-triggered anaphylaxis. Conclusions and relevance: Healthcare professionals must be familiar with recent evidence in the food allergy field and avoid common misunderstandings that may negatively affect prevention, diagnosis and management of this chronic disease.


2012 ◽  
Vol 129 (2) ◽  
pp. AB29 ◽  
Author(s):  
J.M. Factor ◽  
M.R. Lester ◽  
L.M. Mendelson ◽  
J.O. Lee ◽  
J. Sproviero ◽  
...  

2017 ◽  
Vol 30 ◽  
pp. 36-44 ◽  
Author(s):  
Deborah M. Hussey Freeland ◽  
Monali Manohar ◽  
Sandra Andorf ◽  
Benjamin D. Hobson ◽  
Wenming Zhang ◽  
...  

2011 ◽  
Vol 127 (1) ◽  
pp. 290-291 ◽  
Author(s):  
Richard L. Wasserman ◽  
Robert W. Sugerman ◽  
Nana Mireku-Akomeah ◽  
Lyndon Mansfield ◽  
James W. Baker

2020 ◽  
Vol 16 (2) ◽  
pp. 123-128
Author(s):  
Fernanda Chiera ◽  
Lucia Caminiti ◽  
Giuseppe Crisafulli ◽  
Giovanni Battista Pajno

Food allergy is a potentially life-threatening medical condition and a significant public health concern worldwide. The current management consists of strict avoidance of the culprit food and treating any adverse reactions from unintended food ingestion. The increasing prevalence of food allergy encouraged research and clinical trials in the field of specific allergen immunotherapy (AIT) which represents an appealing approach, especially in pediatric age. AIT consists of the gradual administration of growing amounts of the offending allergen in order to induce food desensitization, which is an increase in the threshold for reactivity while continuing on regular exposure to the allergen. AIT can be administered through oral, sublingual, epicutaneous, and subcutaneous routes. Reports on oral immunotherapy (OIT) thus far have been more extensive. The desirable goal is to achieve "post desensitization effectiveness", that is the ability to introduce food without reaction even after a period of discontinuation of the offending food. Other therapeutic approaches are being studied alongside immunotherapy such as modified proteins, probiotics, Chinese herbal supplements, biologic therapies, and DNA vaccines.


2020 ◽  
Vol 68 (6) ◽  
pp. 1152-1155
Author(s):  
Joan H Dunlop

The US Food and Drug Administration’s approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy. While food allergy prevalence has been increasing, this product is the first approved therapy for food allergy. Oral immunotherapy has many similarities to subcutaneous immunotherapy and drug desensitization protocols, but does not lead to sustained unresponsiveness. The studies leading to approval of the Palforzia product demonstrated increase in the amount of peanut protein able to be consumed, with 67% of subjects randomized to the treatment arm able to consume 600 mg of peanut protein in double-blind placebo-controlled food challenge at study exit. However, side effects are an important consideration, and dropout rates in studies of Palforzia ranged from 11% to 21%. Postmarketing surveillance of this product will be critical in assessing its long-term risks and benefits.


PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0170577 ◽  
Author(s):  
Yuka Nagata ◽  
Takeshi Yamamoto ◽  
Michie Hayashi ◽  
Shusaku Hayashi ◽  
Makoto Kadowaki

2011 ◽  
Vol 128 (1) ◽  
pp. 250-251 ◽  
Author(s):  
Mauro Calvani ◽  
Stefano Miceli Sopo ◽  
Valentina Giorgio

Sign in / Sign up

Export Citation Format

Share Document